BamSEC and AlphaSense Join Forces
Learn More

Guided Therapeutics Inc

OTC: GTHP    
Share price (11/22/24): $0.18    
Market cap (11/22/24): $11.3 million

Underwriting Agreements Filter

EX-1
from SCHEDULE 13G/A Underwriting agreement
12/34/56
EX-1.1
from S-1/A 41 pages Shares of Common Stock, Pre-Funded Warrants (Exercisable for Shares) and Common Warrants (Exercisable for Shares) of Guided Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.1
from S-1/A 40 pages Shares of Common Stock, Pre-Funded Warrants (Exercisable for Shares) and Common Warrants (Exercisable for Shares) of Guided Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1
from 8-K/A 5 pages The Unaudited Pro Forma Financial Information Has Been Prepared by the Management of Spectrx Based on the Historical Financial Statements of Spectrx the Unaudited Pro Forma Combined Condensed Financial Information Is Prepared for Informational Purposes Only and Is Not Necessarily Indicative of Future Results or of Actual Results That Would Have Been Achieved Had the Sale Been Consummated at the Beginning of the Periods Presented, Nor Is It Indicative of Future Financial Position or Results of Operations
12/34/56
EX-1
from 8-K 1 page Spectrx, Inc. to Reschedule First Quarter Operating Results and Conference Call
12/34/56
EX-1
from 8-K 29 pages Asset Purchase Agreement
12/34/56
EX-1
from 8-K ~5 pages Spectrx Reports Fourth Quarter and Year-End 2002 Results
12/34/56
EX-1
from 8-K 1 page Spectrx, Inc. Sells Bilichek(r) Product Line to Respironics
12/34/56
EX-1
from 8-K 1 page Spectrx, Inc. Seeks to Terminate Continuous Glucose Monitoring Development Agreement With Abbott Laboratories Spectrx Moves for a Faster Path to Commercialization
12/34/56
EX-1
from 8-K 13 pages Agreement for Termination of Development and Commercialization Agreement
12/34/56
EX-1
from 8-K 1 page Spectrx, Inc. to Trade on NASDAQ Smallcap Market
12/34/56
EX-1
from 8-K 1 page Underwriting agreement
12/34/56
EX-1
from SC 13D/A 1 page Portions of This Document Have Been Omitted (Designated by an Asterisk (*)) and Filed Separately With the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment Dated September 14, 2001. September 4, 2001 via Facsimile Mr. Mark Samuels Chairman & CEO Spectrx, Inc. 6025 a Unity Drive Norcross, Ga 30071 Re: Amendment to the Research & Development License Agreement (October 10, 1996) as Previously Amended by the Parties ("Rdl Agreement") Dear Mark: In Accordance With Our Recent Discussions, Abbott Hereby Delivers the Development Program Notification to Spectrx Pursuant to the Rdl Agreement, and Abbott and Spectrx (The "Parties") Hereby Amend the Terms of the Rdl Agreement as Follows
12/34/56
EX-1
from SC 13D/A ~5 pages Underwriting agreement
12/34/56
EX-1
from SC 13D/A ~5 pages Underwriting agreement
12/34/56
EX-1
from SC 13D/A 1 page Underwriting agreement
12/34/56
EX-1
from SC 13D 1 page Underwriting agreement
12/34/56
EX-1.1
from S-1/A ~50 pages Form of Underwriting Agreement
12/34/56
EX-1.1
from S-1 ~50 pages Form of Underwriting Agreement
12/34/56